The occurrence of asthma in an extensive-stage small-cell lung cancer patient after combination therapy with atezolizumab and anlotinib: a case report
BackgroundExtensive-stage small-cell lung cancer (ES-SCLC) is highly malignant, with early metastasis and high recurrence. Since therapeutic options are limited, ES-SCLC has a characteristically short survival period and extremely poor prognosis. A combination of immune checkpoint inhibitors (ICIs)...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-02-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1333850/full |
| _version_ | 1827339018720772096 |
|---|---|
| author | Wang Deng Wang Deng Juan Chen Juan Chen Xin-Yu Deng |
| author_facet | Wang Deng Wang Deng Juan Chen Juan Chen Xin-Yu Deng |
| author_sort | Wang Deng |
| collection | DOAJ |
| description | BackgroundExtensive-stage small-cell lung cancer (ES-SCLC) is highly malignant, with early metastasis and high recurrence. Since therapeutic options are limited, ES-SCLC has a characteristically short survival period and extremely poor prognosis. A combination of immune checkpoint inhibitors (ICIs) and anti-angiogenic drugs can achieve promising efficacy and safety in patients with ES-SCLC as a second-line or subsequent treatment, extending survival to some extent. However, the clinical outcomes remain mostly unsatisfactory and are sometimes affected by treatment-related adverse events.Case presentationA 57-year-old woman with ES-SCLC was administered a combination therapy of atezolizumab (a PD-L1 inhibitor) and anlotinib [an oral multi-targeted tyrosine kinase inhibitor (TKI)]. She survived for 22 months, with no disease progression during the 28 courses of therapy. Unexpectedly, despite having no history of asthma, the patient developed asthma while receiving this regimen. This is possibly related to T-cell activation and the tumor immune microenvironment, which induce allergic inflammation after PD-L1 blockade.ConclusionsThis is the first report of an asthma-negative ES-SCLC patient who developed asthma after receiving atezolizumab plus anlotinib. Although this combination therapy may effectively extend survival in SCLC patients, asthmatic symptoms should be closely monitored. |
| first_indexed | 2024-03-07T19:44:00Z |
| format | Article |
| id | doaj.art-f3c90f787c334d67ab912354f7dc1db8 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-07T19:44:00Z |
| publishDate | 2024-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-f3c90f787c334d67ab912354f7dc1db82024-02-29T05:16:07ZengFrontiers Media S.A.Frontiers in Immunology1664-32242024-02-011510.3389/fimmu.2024.13338501333850The occurrence of asthma in an extensive-stage small-cell lung cancer patient after combination therapy with atezolizumab and anlotinib: a case reportWang Deng0Wang Deng1Juan Chen2Juan Chen3Xin-Yu Deng4Department of Pulmonary and Critical Care Medicine, Second Affiliated Hospital of Chongqing Medical University, Chongqing, ChinaDepartment of Pulmonary Medicine, Medical Research Center for Pulmonary and Critical Care Medicine, Chongqing, ChinaDepartment of Pulmonary and Critical Care Medicine, Second Affiliated Hospital of Chongqing Medical University, Chongqing, ChinaDepartment of Pulmonary Medicine, Medical Research Center for Pulmonary and Critical Care Medicine, Chongqing, ChinaDepartment of Pulmonary and Critical Care Medicine, Second Affiliated Hospital of Chongqing Medical University, Chongqing, ChinaBackgroundExtensive-stage small-cell lung cancer (ES-SCLC) is highly malignant, with early metastasis and high recurrence. Since therapeutic options are limited, ES-SCLC has a characteristically short survival period and extremely poor prognosis. A combination of immune checkpoint inhibitors (ICIs) and anti-angiogenic drugs can achieve promising efficacy and safety in patients with ES-SCLC as a second-line or subsequent treatment, extending survival to some extent. However, the clinical outcomes remain mostly unsatisfactory and are sometimes affected by treatment-related adverse events.Case presentationA 57-year-old woman with ES-SCLC was administered a combination therapy of atezolizumab (a PD-L1 inhibitor) and anlotinib [an oral multi-targeted tyrosine kinase inhibitor (TKI)]. She survived for 22 months, with no disease progression during the 28 courses of therapy. Unexpectedly, despite having no history of asthma, the patient developed asthma while receiving this regimen. This is possibly related to T-cell activation and the tumor immune microenvironment, which induce allergic inflammation after PD-L1 blockade.ConclusionsThis is the first report of an asthma-negative ES-SCLC patient who developed asthma after receiving atezolizumab plus anlotinib. Although this combination therapy may effectively extend survival in SCLC patients, asthmatic symptoms should be closely monitored.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1333850/fullatezolizumabanlotinibasthmasmall-cell lung cancercombined regimens |
| spellingShingle | Wang Deng Wang Deng Juan Chen Juan Chen Xin-Yu Deng The occurrence of asthma in an extensive-stage small-cell lung cancer patient after combination therapy with atezolizumab and anlotinib: a case report Frontiers in Immunology atezolizumab anlotinib asthma small-cell lung cancer combined regimens |
| title | The occurrence of asthma in an extensive-stage small-cell lung cancer patient after combination therapy with atezolizumab and anlotinib: a case report |
| title_full | The occurrence of asthma in an extensive-stage small-cell lung cancer patient after combination therapy with atezolizumab and anlotinib: a case report |
| title_fullStr | The occurrence of asthma in an extensive-stage small-cell lung cancer patient after combination therapy with atezolizumab and anlotinib: a case report |
| title_full_unstemmed | The occurrence of asthma in an extensive-stage small-cell lung cancer patient after combination therapy with atezolizumab and anlotinib: a case report |
| title_short | The occurrence of asthma in an extensive-stage small-cell lung cancer patient after combination therapy with atezolizumab and anlotinib: a case report |
| title_sort | occurrence of asthma in an extensive stage small cell lung cancer patient after combination therapy with atezolizumab and anlotinib a case report |
| topic | atezolizumab anlotinib asthma small-cell lung cancer combined regimens |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1333850/full |
| work_keys_str_mv | AT wangdeng theoccurrenceofasthmainanextensivestagesmallcelllungcancerpatientaftercombinationtherapywithatezolizumabandanlotinibacasereport AT wangdeng theoccurrenceofasthmainanextensivestagesmallcelllungcancerpatientaftercombinationtherapywithatezolizumabandanlotinibacasereport AT juanchen theoccurrenceofasthmainanextensivestagesmallcelllungcancerpatientaftercombinationtherapywithatezolizumabandanlotinibacasereport AT juanchen theoccurrenceofasthmainanextensivestagesmallcelllungcancerpatientaftercombinationtherapywithatezolizumabandanlotinibacasereport AT xinyudeng theoccurrenceofasthmainanextensivestagesmallcelllungcancerpatientaftercombinationtherapywithatezolizumabandanlotinibacasereport AT wangdeng occurrenceofasthmainanextensivestagesmallcelllungcancerpatientaftercombinationtherapywithatezolizumabandanlotinibacasereport AT wangdeng occurrenceofasthmainanextensivestagesmallcelllungcancerpatientaftercombinationtherapywithatezolizumabandanlotinibacasereport AT juanchen occurrenceofasthmainanextensivestagesmallcelllungcancerpatientaftercombinationtherapywithatezolizumabandanlotinibacasereport AT juanchen occurrenceofasthmainanextensivestagesmallcelllungcancerpatientaftercombinationtherapywithatezolizumabandanlotinibacasereport AT xinyudeng occurrenceofasthmainanextensivestagesmallcelllungcancerpatientaftercombinationtherapywithatezolizumabandanlotinibacasereport |